Rational Pharmacotherapy in Cardiology

Advanced search

The first Russian register of patients with chronic heart failure and atrial fibrillation (RIF-CHF): study design

Full Text:


Chronic heart failure (CHF) and atrial fibrillation (AF) can rightly be called the epidemic of the XXI century, which are associated with high morbidity and mortality of patients. Common risk factors and pathophysiological mechanisms explain the frequent combination of CHF and AF. So far, a number of issues related to management of these patients, remains unresolved. Data on compliance with clinical guidelines and the prevalence of long-term anticoagulant therapy in this group of patients in our country is limited. The first Russian register of CHF and AF (RIF-CHF) is initiated in order to better address this problem. The results allow to develop the most rational therapeutic and diagnostic strategies and, ultimately, to improve the clinical outcomes of such severe patients.

About the Authors

S. N. Tereshchenko
Russian Cardiology Research and Production Complex. Tretya Cherepkovskaya ul. 15a, Moscow, 121552 Russia
Russian Federation

I. V. Zhirov
Russian Cardiology Research and Production Complex. Tretya Cherepkovskaya ul. 15a, Moscow, 121552 Russia
Russian Federation

N. V. Romanova
Russian Cardiology Research and Production Complex. Tretya Cherepkovskaya ul. 15a, Moscow, 121552 Russia
Russian Federation

Yu. F. Osmolovskaya
Russian Cardiology Research and Production Complex. Tretya Cherepkovskaya ul. 15a, Moscow, 121552 Russia
Russian Federation

S. P. Golitsyn
Russian Cardiology Research and Production Complex. Tretya Cherepkovskaya ul. 15a, Moscow, 121552 Russia
Russian Federation


1. Ageev FT, Danielyan MO, Mareev VY et al. Patients with chronic heart failure in the Russian ambulatory practice: contingent features, diagnosis and treatment (studies of AGE-O-CHF). Serdechnaya Nedostatochnost' 2004; 5 (1): 4-7. In Russian (Агеев Ф.Т., Даниелян М.О., Мареев В.Ю. и др. Больные с хронической сердечной недостаточностью в российской амбулаторной практике: особенности контингента, диагностики и лечения (по материалам исследования ЭПОХА-О-ХСН). Сердечная Недостаточность 2004;5 (1):4-7).

2. Ageev FT, Belenkov Yu, Fomin IV et al. Prevalence of chronic heart failure v Evropeyskoy part of the Russian Federation - Data AGE-CHF. Serdechnaya Nedostatochnost' 2006; 7 (1): 112-5. In Russian (Агеев Ф.Т., Беленков Ю.Н., Фомин И.В. и др. Распространенность хронической сердечной недостаточности в Европейской части Российской Федерации – данные ЭПОХА-ХСН. Сердечная Недостаточность 2006;7 (1): 112-5).

3. Fomin IV. Arterial hypertension in the Russian Federation - the past 10 years. What's next? Serdtse 2007; 6 (3): 1-6. In Russian (Фомин И.В. Артериальная гипертония в Российской Федерации – последние 10 лет. Что дальше? Сердце 2007;6 (3):1-6).

4. Bleumink G., Knetsch A., Sturkenboom M. Quantifying the heart failure epidemic: prevalence, incidence rate, lifetime risk and prognosis of heart failure: the Rotterdam Study. Eur Heart J 2004;25:1614-9.

5. Ho K., Pinsky J., Kannel W., Levy D. The epidemiology of heart failure: the Framingham Study. J Am Coll- Cardiol 1993;22:6A-13A.

6. Mareev VY, Danielyan MO, Belenkov YN; On behalf of the working group study AGE-O-CHF. Comparative characteristics of patients with CHF, depending on the size of the PV on the results of the Russian multicenter study AGE-O-CHF. Serdechnaya Nedostatochnost' 2006; 7 (4): 164-71. In Russian (Мареев В.Ю., Даниелян М.О., Беленков Ю.Н. От имени рабочей группы исследования ЭПОХА-О-ХСН. Сравнительная характеристика больных с ХСН в зависимости от величины ФВ по результатам Российского многоцентрового исследования ЭПОХА-О-ХСН. Сердечная Недостаточность 2006;7 (4):164-71).

7. Cheng RK, Cox M, Neely ML, et al. Outcomes in patients with heart failure with preserved, borderline, and reduced ejection fraction in the Medicare population. Am Heart J 2014;168 (5):721-30.

8. The SOLVD Investigators. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med 1992;327:685-91.

9. CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med 1987;316:1429-35.

10. Wang T.J., Larson M.G., Levy D. et al. Temporal relations of atrial fibrillation and congestive heart failure and their joint influence on mortality: the Framingham Heart Study. Circulation 2003;107:2920— 5.

11. Nieuwlaat R, Capucci A, Camm AJ, et al. Atrial fibrillation management: a prospective survey in ESC member countries: the Euro Heart Survey on Atrial Fibrillation. EurHeart J 2005;26:2422-34.

12. Cleland JG, Swedberg K, Follath F, et al. The EuroHeart Failure survey programme—a survey on the quality of care among patients with heart failure in Europe. Part 1: patient characteristics and diagnosis. Eur Heart J 2003;24:442-63.

13. Khan MA, Ahmed F, Neyses L, Mamas MA. Atrial fibrillation in heart failure: The sword of Damoclesrevisited. World J Cardiol 2013; 5(7): 215-27.

14. National guidelines on the diagnosis and treatment of chronic heart failure (fourth revision). Serdechnaya Nedostatochnost' 2013; 14 (7): 1-25. In Russian (Национальные рекомендации по диагностике и лечению хронической сердечной недостаточности (четвертый пересмотр). Сердечная Недостаточность 2013; 14(7): 1-25).

15. Lip GYN, Laroche C, Popescu M, et al. Heart failure in patients with atrial fibrillation in Europe: a report from the EURObservational Research Programme Pilot survey on Atrial Fibrillation. ur J Heart Fail 2015; 17: 570-82.

16. Hart R., Pearce L., Aguilar M. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med 2007;146:857—67.

17. Ferreira J, Ezekowitz MD, Connolly SJ, et al; RE-LY Investigators. Dabigatran compared with warfarin in patients with atrial fibrillation and symptomatic heart failure: a subgroup analysis of the RE-LY trial. Eur J Heart Fail 2013;15(9):1053-61.

18. Patel MR, Mahaffey KW, Garg J et al.; ROCKET AF Investigators. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011;365: 883-91.

19. Connolly SJ, Eikelboom J, Joyner C et al.; AVERROES Steering Committee and Investigators. Apixaban in patients with atrial fibrillation. N Engl J Med 2011; 364: 806-17.

20. Nieuwlaat R., Eurlings L.W., Cleland J.G. et al. Atrial fibrillation and heart failure in cardiology practice: reciprocal impact and combined management from the perspective of atrial fibrillation: results of the Euro Heart Survey on atrial fibrillation. J Am Coll Cardiol 2009;53:1690—8.

21. Kakkar A.K., Mueller I., Bassand J.P. et al.; GARFIELD Registry Investigators. Risk profiles and antithrombotic treatment of patients newly diagnosed with atrial fibrillation at risk of stroke: perspectives from the international, observational, prospective GARFIELD registry. PLoS One 2013;8:e63479.

22. Lamberts M, Lip GY, Ruwald MH, et al. Antithrombotic treatment in patients with heart failure and associated atrial fibrillation and vascular disease: a nationwide cohort study. JACC 2014; 63(24):2689-98.

23. Roy D, Talajic M, Nattel S, et al. Rhythm control versus rate control for atrial fibrillation and heart failure. N Engl J Med 2008;358:2667-2677.

24. Rienstra M., Damman K., Mulder B. Beta-Blockers and Outcome in Heart Failure and Atrial Fibrillation. A Meta-Analysis. JCHF 2013;1(1):21—8.

25. Kotecha D., Holmes J., Krum H., et al. Efficacy of β-blockers in patients with heart failure plus atrial fibrillation: an individualpatient data meta-analysis. Lancet 2014;S0140-6736(14): 61373—8.

26. Packer M., Fowler M., Roecker E. Effect of carvedilol on the morbidity of patients with severe chronic heart failure: results of the carvedilol prospective randomized cumulative survival (COPERNICUS) study. Circulation 2002;106:2194—9.

27. MERIT-HF Study Group. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 1999;353:2001—7.

28. CIBIS-II Investigators and Committees. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomized trial. Lancet 1999;353:9—13.

29. Flather M., Shibata M., Coats A. Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). Eur Heart J 2005;26:215—25.

30. Li SJ, Sartipy U, Lund LH, et al. Prognostic Significance of Resting Heart Rate and Use of Beta-Blockers in Atrial Fibrillation and Sinus Rhythm in Patients With Heart Failure and Reduced Ejection Fraction: Findings From the Swedish Heart Failure Registry. Circ Heart Fail 2015;8(5):871-9.

31. Pedersen O., Bagger H., Kober L., Torp-Pedersen C., for the TRACE Study Group. Impact of congestive heart failure and left ventricular systolic function on the prognostic significance of atrial fibrillation and atrial flutter following acute myocardial infarction. Int J Cardiol 2005;100:65-71.

32. Parkash R, Tang AS, Sapp JL, et al. Approach to the catheter ablation technique of paroxysmal and persistent atrial fibrillation: a meta-analysis of the randomized controlled trials. J Cardiovasc Electrophysiol 2011;22:729-38.

33. Piccini JP, Lopes RD, Kong MH, et al. Pulmonary vein isolation for the maintenance of sinus rhythm in patients with atrial fibrillation: a metaanalysis of randomized, controlled trials. Circ Arrhythm Electrophysiol 2009;2:626-33.

34. Jones DG, Haldar SK, Hussain W, et al. A randomized trial to assess catheter ablation versus rate control in the management of persistent atrial fibrillation in heart failure. J Am Coll Cardiol 2013;61(18):1894-903.

35. Marrouche NF, Brachmann J; CASTLE-AF Steering Committee. Catheter ablation versus standard conventional treatment in patients with left ventricular dysfunction and atrial fibrillation (CASTLE-AF) study design. Pacing Clin Electrophysiol 2009;32(8):987-94.

For citation:

Tereshchenko S.N., Zhirov I.V., Romanova N.V., Osmolovskaya Yu.F., Golitsyn S.P. The first Russian register of patients with chronic heart failure and atrial fibrillation (RIF-CHF): study design. Rational Pharmacotherapy in Cardiology. 2015;11(6):577-581. (In Russ.)

Views: 986

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.

ISSN 1819-6446 (Print)
ISSN 2225-3653 (Online)